4531
Yuki Gosei Kogyo Co.,Ltd.
有機合成薬品工業
- Industry
- Chemicals
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(million JPY)
Mar 2021
11,091
Mar 2022
12,361
Mar 2023
12,839
Mar 2024
12,932
Mar 2025
15,128
Operating profit(million JPY)
Mar 2021
218
Mar 2022
413
Mar 2023
897
Mar 2024
1,125
Mar 2025
1,216
Operating profit margin(%)
Mar 2021
1.97
Mar 2022
3.34
Mar 2023
6.99
Mar 2024
8.7
Mar 2025
8.04
Profit before tax(million JPY)
Mar 2021
319
Mar 2022
289
Mar 2023
641
Mar 2024
905
Mar 2025
1,124
Profit(million JPY)
Mar 2021
288
Mar 2022
248
Mar 2023
556
Mar 2024
776
Mar 2025
896
Total assets(million JPY)
Mar 2021
20,998
Mar 2022
21,172
Mar 2023
22,118
Mar 2024
24,370
Mar 2025
26,871
Cash and cash equivalents(million JPY)
Mar 2021
1,256
Mar 2022
1,856
Mar 2023
1,143
Mar 2024
588
Mar 2025
973
Cash flows from operating activities(million JPY)
Mar 2021
352
Mar 2022
1,787
Mar 2023
668
Mar 2024
388
Mar 2025
2,143
Cash flows from investing activities(million JPY)
Mar 2021
-648
Mar 2022
-442
Mar 2023
-1,237
Mar 2024
-1,894
Mar 2025
-3,248
Cash flows from financing activities(million JPY)
Mar 2021
106
Mar 2022
-772
Mar 2023
-158
Mar 2024
948
Mar 2025
1,496
Return on equity(%)
Mar 2021
2.69
Mar 2022
2.26
Mar 2023
4.95
Mar 2024
6.49
Mar 2025
7.02
Equity ratio(%)
Mar 2021
52.1
Mar 2022
52
Mar 2023
51.9
Mar 2024
51
Mar 2025
48.8
Earnings per share(JPY per share)
Mar 2021
13.22
Mar 2022
11.37
Mar 2023
25.51
Mar 2024
35.57
Mar 2025
41.4
Net assets per share(JPY per share)
Mar 2021
501.55
Mar 2022
504.23
Mar 2023
525.98
Mar 2024
569.6
Mar 2025
608.38
Dividend per share(JPY per share)
Mar 2021
3
Mar 2022
4
Mar 2023
7
Mar 2024
8
Mar 2025
9
Payout ratio(%)
Mar 2021
22.69
Mar 2022
35.18
Mar 2023
27.44
Mar 2024
22.49
Mar 2025
21.74
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.